73 results about "Streptococcal M protein" patented technology

The invention provides an mVSV virus vector, i.e., attenuated mVSV obtained after multiple modification mutations occur to an M protein amino acid site of a wild Indiana strain VSV, and an optimized heterologous antigen gene is preferentially integrated to a double cloning site area of an mVSV packaging core plasmid pmVSV-Core at the same time. The mVSV virus vector vaccine comprises a heterologous antigen gene which fuses or embeds a target virus between G and L genes of an mVSV vector envelope, wherein the antigen gene comprises an enveloped and embedded antigen gene encoding the target virus, an embedded combination antigen gene or a fused antigen gene; the mVSV virus vector is embedded or fused with a dominant antigen of spike protein S of an SARS-CoV-2 pathogen; the dominant antigen is preferably selected from a receptor binding domain of spike protein S, namely RBD; and a COVID-19 vaccine based on mVSV mediation is formed. The vaccine has good prevention or treatment effect on COVID-19 infected people.

The invention discloses a porcine reproductive and respiratory syndrome divalent recombination adenovirus vaccine and the preparation method thereof. The invention belongs to the technical field of biological vaccine preparation. The vaccine can be prepared by the following steps: a GP5-2A-M fusion protein gene can be constructed by inserting an FMDV2A gene with self craking between PRRSV GP5 and M protein; homologous recombination is carried out on the GP5-2A-M fusion protein gene and adenovirus backbone plasmid pAdEasy-1; recombination adenovirus rAd-GP5-2A-M is prepared by restriction enzyme and HEK-293A cells transfection, and the divalent recombination adenovirus vaccine is prepared by the technology and the steps such as purification, amplification, and the like. After expression, the aggregate protein GP5-2A-M constructed by the invention is self cracked into GP5 and M protein, as well as exerts the viral neutralization of GP5 and the immune function of the M protein; the vaccine has stable titer with the virulent valence being 10<10.43>TCID<50>/1.0ml, as well as has both the duplication characteristic of a routine attenuated vaccine and the safety of an inactivated vaccine; the divalent recombination adenovirus vaccine can be popularized in and applied to the control work of porcine reproductive and respiratory syndrome.

The invention relates to a respiratory syncytial virus vaccine, and the preparation method and application, in particular to an application of escherichia coli to express and recombinant respiratory syncytial virus G protein and mutation G protein, and preparation vaccine with nontoxic typed escherichia coli heat labile enterotoxin, for human or animal preventive inoculation, and for respiratory syncytial virus resistance, belonging to the field of biotechnology. The respiratory syncytial virus vaccine is characterized in that: the respiratory syncytial virus subunits vaccine comprises lopped respiratory syncytial virus RSV protein G, and further comprises nontoxic typed escherichia coli heat labile enterotoxin LT adjuvant. The vaccines are lopped respiratory syncytial virus RSV protein G containing amino acid between aa130 and 230 of the original G protein, and substitutes the amino acid CAWIC (CX3C module ordered) between aa182 and 186 with the amino acid YLEKESIYY (CTL epitope) on the RSV M protein, forming the GCIL protein. The respiratory syncytial virus vaccine has the advantages of remarkable practical significance for preventing human respiratory syncytial virus infection.

The invention discloses recombinant porcine reproductive and respiratory syndrome virus (PRRSV) virus-like particles (VLP) and a preparation method and an application thereof. Based on comparative analysis of GP5 of a PRRSV epidemic strain and an M gene sequence, a GP5 and M tandem sequence GP5M is synthesized artificially, the synthesized GP5M gene sequence is cloned into a vector with a pBAC5 plasmid as a skeleton, the baculovirus transfer vector pBAC-PRRSVGP5M is obtained, the recombinant bacmid rBacmid-GP5M is obtained, sf9 cells are transfected with the bacmid, and the recombinant baculovirus Ac-PRRSVGP5M is obtained. The PRRSV GP5 and M protein are expressed efficiently by the recombinant baculovirus, and the virus-like particles are formed. A subunit vaccine prepared by the proteinexpressed by the recombinant baculovirus can induce a body to produce a specific immune response after immunizing animals and can protect the pig body against the strong poison attacking of porcine reproductive and respiratory syndrome virus.

The invention discloses porcine reproductive and respiratory syndrome virus M protein CTL cell epitopes and application thereof. The identification of the epitopes comprises the following steps of: fusing and cloning a M protein gene of a porcine reproductive and respiratory syndrome virus CH-1a strain and a mouse ubiquitin gene to form a DNA vaccine and also form recombination viruses, expressing an M protein, of a WR strain vaccinia virus; immunizing a BALB/c mouse according to a Priming-Boosting policy, separating the mouse splenic lymphocyte, culturing and stimulating a CTL short peptide in vitro predicted and synthesized by a bioinformatic method, and using the flow cytometry and enzyme-linked immunospot technology to identify two CTL epitopes that are K93FITSRCRL and F57GYMTFVHF. The identification of the PRRSVM protein CTL cell epitopes lays a certain theoretical foundation for the PRRS cell immune mechanism and the novel epitope pepetide vaccine and has an instructing significance for the theoretical study on PRRS preventing and control technology.

The invention provides a co-expression porcine reproduction and a method for preparing a dual-gene nucleic acid vaccine of respiratory syndrome virus (PRRSV) ORF5 and ORF6. The method comprises the following steps: amplifying the whole gene sequences of the PRRSV ORF5 and the ORF6 respectively by an RT-PCR method, and inserting two genes into two multiple cloning sites of a mammalian eukaryotic expression vector pIRES to obtain recombinant plasmids pIRES-ORF5 and ORF6; transfecting the recombinant plasmids with CHO cells to establish a stable expression cell line; and detecting the transcription of the genes PRRSV ORF5 and ORF6 by an RT-PCR method, and detecting the expressions and the immune activities of GP5 and M proteins through the SDS-PAGE and the Western blot. The nucleic acid vaccine can generate GP5 proteins and M proteins in animals continuously so that organisms generate antibodies against both of the proteins continuously, thus the nucleic acid vaccine provides long-lasting immune protection for pig bodies, and has wide application prospect in PRRS prevention and control.

The invention discloses a novel PhyA-M protein and application of the same. The PhyA-M protein is a heat-resistant phytase and can be used for decomposition of phytic acids or phytates. The invention also discloses a gene for encoding the PhyA-M protein, and a carrier and a host cell which comprise the gene. The PhyA-M protein has wide application prospect in fields such as feedstuff additives and so on.

The invention discloses a small interfering RNA limiting SARS coronavirus M protein gene expression and the coding gene and the application. The small interfering RNA limiting SARS coronavirus M protein gene expression is about at least one double stranded RNA sequence among the following 1) and 2): 1). Nucleotide sequence for sequence 1 in sequence list is arranged for the sense strand; nucleotide sequence for sequence 2 in sequence list is arranged for the antisense strand; 2). Nucleotide sequence for sequence 3 in sequence list is arranged for the sense strand; nucleotide sequence for sequence 4 in sequence list is arranged for the antisense strand. The invention has an advantage of playing an important role in preparing drugs using small interfering RNA limiting SARS coronavirus M protein gene expression or an expression vector carrying the coding gene for small interfering RNA limiting SARS coronavirus M protein gene expression as active component.

The invention relates to the technical field of biology, in particular to a COVID-19 pseudovirus as well as a preparation method and application thereof. The COVID-19 pseudovirus is formed by virus packaging of coat protein particles and helper plasmids, wherein the coat protein particles comprise plasmids for expressing a COVID-19 S protein, plasmids for expressing a COVID-19 M protein and plasmids for expressing a COVID-19 E protein. The COVID-19 pseudovirus is packaged by adopting a three-plasmid system, and the S/M/E protein is used for replacing expression a VSV-G protein, so that the COVID-19 pseudovirus is stronger in infection capability and higher in sensitivity compared with the pseudovirus only containing the S protein. Moreover, the COVID-19 pseudovirus carries two fluorescentreporter groups, and different fluorescent reporter groups can be applied to different scenes, so that the COVID-19 pseudovirus is simpler and more convenient to apply.

The invention discloses a DNA (deoxyribonucleic acid) level-based highly pathogenic blue-eared pig disease JEV (Japanese encephalitis virus) replicon vaccine and an application thereof. In the invention, primer amplification is carried out to obtain GP5 and M genes of a highly pathogenic blue-eared pig disease virus XH strain, an FMDV-2A sequence is inserted between the two genes by utilizing a fusion PCR (polymer chain reaction) method to obtain a G-2A-M segment, and finally the G-2A-M segment is cloned into pJEV-REP by utilizing two restriction enzyme cutting sites SpeI and SalI; besides, an IRES (internal ribosome entry site) sequence (G-2A-M-IRES) is inserted into the downstream of the G-2A-M segment, thus M protein can produce a real N terminal; and the G-2A-M-IRES segment is inserted into the pJEV-REP by utilizing two restriction enzyme cutting sites SalI-HF and SpeI, and finally a highly pathogenic blue-eared pig disease vaccine which is based on a JEV replicon and can express GP5 and M proteins is constructed.

Isolated M proteins, or M-like proteins, of Streptococcus iniae, encoding nucleic acids, genetic constructs and antibodies which bind the isolated M proteins are provided. Also provided are isoforms and/or fragments of the M proteins, or M-like proteins, that display reduced fibrinogen binding. The isolated M proteins, antibodies and encoding nucleic acids maybe useful for diagnosis, immunization and/or therapy of Streptococcus iniae infections of animals such as fish and humans.

The invention provides an IHNV genetic engineering oral microsphere vaccine and a preparation method and application thereof. The vaccine is characterized in that the preparation method comprises thefollowing steps: construction of an expression vector pET-22b-m, expression of M protein in the expression vector pET-22b-m, and preparation of the oral microsphere vaccine. The microsphere vaccine has the advantages that adopted sodium alginate and chitosan are natural polysaccharides, safe and free of toxics and pollution, and can stably increase the stability and homogeneity of target protein,the chitosan itself can inhibit the bacterial activity, and a guarantee is provided for the long-term and stable preservation of the microsphere vaccine. The provided preparation method is simple in process and takes less time, and the success rate of the preparation is high. The provided IHNV genetic engineering oral microsphere vaccine has good release properties and acid resistance, and it is found through immune experiments that the vaccine has a certain immune protection effect on rainbow trout.

The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position (21), a leucine changed to a phenylalanine at position (111) and a methionine changed to an arginine at position (51). Another M protein mutant includes a glycine changed to a glutamic acid at position (22) and a methionine changed to an arginine at positions (48) and (51). Yet another VSV M protein mutant includes a glycine changed to a glutamic acid at position (22), a leucine changed to a phenylalanine at position (110) and a methionine changed to an arginine at positions (48) and (51). The present invention is directed also to recombinant VSVs (rVSV) having these M mutants and to vaccines based on the rVSV having the M mutants of the present invention. These new rVSVs having the mutant M were significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31° C., and of poor replication or incapable of replication at about 37° C. or higher.